Cargando…
Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate
The aim of this study was to prepare and characterize the imatinib mesylate (IM)-loaded gamboge-based ISG system for local administration of an anticancer agent against colorectal carcinoma. The ISG formulations were prepared in dimethyl sulfoxide (DMSO) and N-methyl-2-pyrrolidone (NMP). The physico...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529659/ https://www.ncbi.nlm.nih.gov/pubmed/37754418 http://dx.doi.org/10.3390/gels9090737 |
_version_ | 1785111418342735872 |
---|---|
author | Jitrangsri, Kritamorn Khaing, Ei Mon Intaraphairot, Torsak Phaechamud, Thawatchai Mahadlek, Jongjan |
author_facet | Jitrangsri, Kritamorn Khaing, Ei Mon Intaraphairot, Torsak Phaechamud, Thawatchai Mahadlek, Jongjan |
author_sort | Jitrangsri, Kritamorn |
collection | PubMed |
description | The aim of this study was to prepare and characterize the imatinib mesylate (IM)-loaded gamboge-based ISG system for local administration of an anticancer agent against colorectal carcinoma. The ISG formulations were prepared in dimethyl sulfoxide (DMSO) and N-methyl-2-pyrrolidone (NMP). The physicochemical properties, drug release profile, and cytotoxicity of the developed formulations were assessed. The developed ISG demonstrated Newtonian flow behavior with acceptable rheological and mechanical properties. The viscosity of the developed ISG, measured at less than 80 cP, and the applied forces of less than 50 N·mm, indicated easy administration using clinical injection techniques. Upon contact with an aqueous phase, the ISG immediately formed a porous cross-sectional structure, enabling sustained release of IM over 14 days. The release profile of IM was fitted to the quasi-Fickian diffusion mechanism, and the release rate could be controlled by the types of solvent and the amount of IM content. The developed IM-loaded gamboge ISG effectively inhibited colorectal cancer cells, including HCT116 and HT29 cell lines, with less than 20% cell viability observed at a concentration of 1% w/w IM after 2 days of incubation. This suggests that the developed ISG may potentially serve as an injectable system for localized anticancer delivery against colorectal cells, potentially reducing the side effects of systemic chemotherapy and improving patient adherence. |
format | Online Article Text |
id | pubmed-10529659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105296592023-09-28 Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate Jitrangsri, Kritamorn Khaing, Ei Mon Intaraphairot, Torsak Phaechamud, Thawatchai Mahadlek, Jongjan Gels Article The aim of this study was to prepare and characterize the imatinib mesylate (IM)-loaded gamboge-based ISG system for local administration of an anticancer agent against colorectal carcinoma. The ISG formulations were prepared in dimethyl sulfoxide (DMSO) and N-methyl-2-pyrrolidone (NMP). The physicochemical properties, drug release profile, and cytotoxicity of the developed formulations were assessed. The developed ISG demonstrated Newtonian flow behavior with acceptable rheological and mechanical properties. The viscosity of the developed ISG, measured at less than 80 cP, and the applied forces of less than 50 N·mm, indicated easy administration using clinical injection techniques. Upon contact with an aqueous phase, the ISG immediately formed a porous cross-sectional structure, enabling sustained release of IM over 14 days. The release profile of IM was fitted to the quasi-Fickian diffusion mechanism, and the release rate could be controlled by the types of solvent and the amount of IM content. The developed IM-loaded gamboge ISG effectively inhibited colorectal cancer cells, including HCT116 and HT29 cell lines, with less than 20% cell viability observed at a concentration of 1% w/w IM after 2 days of incubation. This suggests that the developed ISG may potentially serve as an injectable system for localized anticancer delivery against colorectal cells, potentially reducing the side effects of systemic chemotherapy and improving patient adherence. MDPI 2023-09-12 /pmc/articles/PMC10529659/ /pubmed/37754418 http://dx.doi.org/10.3390/gels9090737 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jitrangsri, Kritamorn Khaing, Ei Mon Intaraphairot, Torsak Phaechamud, Thawatchai Mahadlek, Jongjan Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate |
title | Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate |
title_full | Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate |
title_fullStr | Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate |
title_full_unstemmed | Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate |
title_short | Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate |
title_sort | injectable gamboge-based in situ gel for sustained delivery of imatinib mesylate |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529659/ https://www.ncbi.nlm.nih.gov/pubmed/37754418 http://dx.doi.org/10.3390/gels9090737 |
work_keys_str_mv | AT jitrangsrikritamorn injectablegambogebasedinsitugelforsustaineddeliveryofimatinibmesylate AT khaingeimon injectablegambogebasedinsitugelforsustaineddeliveryofimatinibmesylate AT intaraphairottorsak injectablegambogebasedinsitugelforsustaineddeliveryofimatinibmesylate AT phaechamudthawatchai injectablegambogebasedinsitugelforsustaineddeliveryofimatinibmesylate AT mahadlekjongjan injectablegambogebasedinsitugelforsustaineddeliveryofimatinibmesylate |